Professional Documents
Culture Documents
https://doi.org/10.1007/s40119-018-0118-x
BRIEF REPORT
A. Elbadawi
Department of Cardiovascular Medicine, University Keywords: Anti-platelets; Percutaneous
of Texas Medical Branch, Galveston, TX, USA coronary intervention; Stent thrombosis;
Therapeutic hypothermia
I. Y. Elgendy (&)
Division of Cardiovascular Medicine, University of
Florida, Gainesville, FL, USA
e-mail: iyelgendy@gmail.com INTRODUCTION
A. H. Mohamed K. Barssoum E. Alotaki
Internal Medicine Department, Rochester General
Out of hospital cardiac arrest (OHCA) carries a
Hospital, Rochester, NY, USA significant mortality worldwide [1]. Therapeutic
hypothermia (TH) as well as early percutaneous
G. O. Ogunbayo K. M. Ziada coronary intervention (PCI) for patients with
Department of Cardiovascular Medicine, University
of Kentucky, Lexington, KY, USA OHCA and suspected myocardial injury have
186 Cardiol Ther (2018) 7:185–189
been shown to improve outcomes [2, 3]. The agents (ticagrelor or prasugrel) were reported.
impact of TH on outcomes of PCI remains The study designs, intervention strategies and
debatable. Some studies have demonstrated main outcomes were extracted by two investi-
higher incidence of stent thrombosis associat- gators (A.H and K.B). Discrepancies among
ing TH after PCI [3, 4]. Experimental studies investigators were resolved by consensus. The
have raised concerns regarding the efficacy of primary outcome was in-hospital definite stent
clopidogrel in cases of hypothermia, possibly by thrombosis. Identified cases of definite stent
augmenting adenosine diphosphate (ADP)- thrombosis were established in all studies in
induced platelet aggregation [5]. Hypothermia accordance with the Academic Research Con-
also impairs the pharmacokinetic profile of sortium definition [7]. Secondary outcomes
clopidogrel including its absorption, and enzy- included in-hospital mortality and major
matic activation to the active metabolites [1, 5]. bleeding. Fixed-effects and random-effects risk
Some studies showed a better platelet inhibition ratios (RRs) were estimated using Man-
with ticagrelor and prasugrel compared to tel–Haenszel method. Heterogeneity was calcu-
clopidogrel in TH [2, 6]. However, the clinical lated using the I2 test. Statistical analyses were
translation of these experimental observations conducted using RevMan 5.0 software
is not clear. We conducted this meta-analysis to (Cochrane Collaboration, Oxford, UK). The
evaluate the available clinical evidence com- current analysis was conducted in accordance
paring the use of clopidogrel versus newer with the PRISMA (Preferred Reporting Items for
P2Y12 antagonists in cases of TH after PCI. Systematic Reviews and Meta-Analyses) Check-
list (Supplemental Table 1). We used the New-
castle–Ottawa score to assess the quality of
METHODS included studies [8].
This article does not contain any studies
We performed a computerized search of MED- with human participants or animals performed
LINE, EMBASE, and COCHRANE databases by any of the authors.
through December 2017, for studies on sur-
vivors of OHCA receiving TH who underwent
PCI. A similar search strategy was also done for RESULTS
abstracts of the major scientific sessions
(American College of Cardiology, European Our final analysis included five studies with a
Society of Cardiology, the American Heart total of 290 patients. One study was a prospec-
Association and European Association of Car- tive randomized-controlled trial [2], while two
diothoracic Anesthesiologists) up to December studies were prospective non-randomized [1, 6]
2017. We further screened the bibliographies of and two studies were retrospective studies [3, 4].
the retrieved studies as well as clinicaltrials.gov In those studies, TH protocols included main-
for any relevant studies not retrieved by the taining a temperature of 32–34 °C for 12–24 h
initial search. Studies were included when (Table 1). In all studies, patients received peri-
clinical outcomes for patients receiving clopi- procedural aspirin and P2Y12 receptor inhibi-
dogrel versus one of the newer antiplatelet tors via nasogastric tube. Baseline characteristics
Fig. 1 Forrest plot for definite stent thrombosis for clopidogrel versus newer anti-platelet agents. ST stent thrombosis
Cardiol Ther (2018) 7:185–189 187
of included studies are described in Supple- bias could not be assessed due to the few num-
mental Table 2. Using Newcastle–Ottawa score ber of studies included in the analysis.
all studies were assessed to have good quality,
except one study of fair quality [2] (Supple-
mental Table 3). The incidence of stent throm- DISCUSSION
bosis was not different between patients
receiving clopidogrel 9 (6.1%) versus those This meta-analysis of five clinical studies with a
receiving newer agents 9 (6.3%) (RR 0.92; 95% total of 290 patients demonstrated that among
CI 0.35–2.38; p = 0.86) with moderate hetero- patients receiving TH after PCI, no significant
geneity (I2 = 45%) (Fig. 1). Sub-group analysis difference existed between clopidogrel and
showed no difference between clopidogrel ver- newer agents (ticagrelor or prasugrel) regarding
sus newer agents in retrospective studies (RR in-hospital stent thrombosis, all-cause mortality
0.92; 95% CI 0.31–2.71; p = 0.88) compared or major bleeding. Overall, the incidences of
with prospective studies (RR 0.91; 95% CI stent thrombosis in our analysis (6.1% with
0.12–6.91; p = 0.93) (Pinteraction = 0.99). Further clopidogrel and 6.3% with newer agents) was
sub-group analysis showed no difference when higher than reported incidences of stent
comparing clopidogrel versus ticagrelor (RR thrombosis in non-hypothermia conditions [9].
1.09; 95% CI 0.37–3.24; p = 0.88) or clopidogrel Little evidence is available regarding the
versus prasugrel (RR 0.38; 95% CI 0.09–1.51; optimal dual antiplatelet regimen in OHCA
p = 0.17) (Pinteraction = 0.24). In-hospital all- patients receiving TH after PCI. TH treatment as
cause mortality (reported in three studies) was well as the post-resuscitation syndrome have
not statistically different between clopidogrel been both associated with a pro-thrombotic
20 (24.4%) and newer agents 11 (15.5%) (RR state [5]. In addition, altered absorption and
1.38; 95% CI 0.72–2.65; p = 0.34; I2 = 0%) pharmacokinetics of different medications has
[1, 4, 6]. Similarly, three studies reported major been reported with TH [1, 5].
bleeding events [1, 4, 6], and no significant The results of our meta-analysis did not show
difference was detected between clopidogrel 8 a difference in clinical outcomes between
(9.8%) and newer agents 7 (9.9%) (RR 0.89; 95% hypothermia patients receiving clopidogrel
CI 0.33–2.40; p = 0.82; I2 = 0%). Publication versus newer agents. The lack of difference in
188 Cardiol Ther (2018) 7:185–189
5. Högberg C, Erlinge D, Braun OÖ. Mild hypothermia 9. Lagerqvist B, Carlsson J, Fröbert O, Lindbäck J,
does not attenuate platelet aggregation and may even Scherstén F, Stenestrand U, James SK. Stent throm-
increase ADP-stimulated platelet aggregation after bosis in Sweden. Circ Cardiovasc Interv.
clopidogrel treatment. Thromb J. 2009;7:2. 2009;2:401–8.